Introduction
Allogeneic bone marrow transplantation (allo-BMT) has become a well-established modality to treat a variety of hematological disorders. However, prolonged immune deficiency after allo-BMT remains a major cause of transplant-related mortality associated with opportunistic infections. 1 This immune deficiency is most pronounced in the T-cell lineage due to a severe delay in T-cell development in thymus. Previous studies have shown that there are two pathways responsible for T-cell immunity reconstruction following allo-BMT: thymicdependent T-cell regeneration from donor-derived bone marrow progenitors and thymic-independent peripheral expansion of mature T-cell populations. 2, 3 It was believed that the peripheral expansion only gives rise to limited immune competence, mainly because T lymphocytes regenerated from this pathway show limited T-cell receptor diversity and a highly activated phenotype, which results in T-cell dysfunction and increased susceptibility to cell death. 4 Current concepts hold that the capacity of the host to restore immune competence depends primarily on the extent to which thymic pathways contribute to T-cell regeneration. Unfortunately, several studies have shown that age-and therapy-related changes that occur within the thymus of hosts experiencing allo-BMT lead to a significant defect in thymopoiesis and limit the efficiency of thymic-dependent T-cell regeneration. 5, 6 Therefore, identification of new approaches to enhance thymopoiesis following allo-BMT is greatly needed.
Interleukin-7 (IL-7) has recently been identified as a potent thymopoietic agent, which is indispensable for murine T and B lymphopoiesis and essential for human T-cell development. 7 The mice deficient for IL-7 or IL-7 receptor all display severely impaired B-and T-cell development. 8, 9 In humans, a defect in the IL-7 or IL-7 receptor gene will result in a severe combined immunodeficiency syndrome with a complete lack of T cells. 10 A number of studies have attempted to correct defects in thymopoiesis in bone marrow transplantation (BMT) hosts by administration of exogenous IL-7, and indeed some of them have demonstrated that injection of IL-7 after BMT resulted in the normalization of thymocyte numbers, thymocyte subsets and T-lymphocyte proliferative responses to mitogens and antigens. 11, 12 However, direct effects of IL-7 on thymopoiesis depend on the high dose of IL-7 systemically administered because of rapid consumption of this cytokine by proliferating peripheral T cells. 13 The dose-related adverse effects including autoimmune disease and lymphoproliferation and/or lymphoma may limit its clinical application. 14 Bone marrow stromal cells (MSCs), the most important component of bone marrow hematopoietic microenvironment, control and regulate hematopoiesis by providing hematopoietic growth factors, facilitating cell-to-cell interactions and elaborating matrix proteins. 15 Because MSCs can be transplantated and possess multiorgan homing capacity, co-transplantation of MSCs has become an attractive new form of cellular therapy in the transplantation area. 16, 17 It has been shown that co-transplantation of donor-derived MSCs could reconstruct bone marrow microenvironment damaged by pre-BMT conditioning treatment, leading to an increased hematopoietical and immunological reconstitution, and free of GVHD due to their immunosuppressive effects. 18 Furthermore, MSCs have been used as vehicles for gene therapy because they can be easily isolated and in vitro expanded, and can be transduced efficiently to provide stable, long-term gene expression. 19, 20 Therefore, in the present study, we sought to examine the capacity of donor-derived MSC-mediated IL-7 gene therapy to restore immune competence following T-cell depleted allo-BMT and investigate their effects on GVHD. The results show that our developed approach accelerates immune reconstitution through both enhancing thymopoiesis and expanding peripheral T lymphocytes. Additionally, this strategy can also prevent or alleviate GVHD-induced tissue inflammation and mortality.
Results
Detection of IL-7 protein in the supernatant of AdIL-7-transduced bone marrow stromal cells
The expression of IL-7 in lysates of IL-7 gene-transduced MSCs was confirmed by Western blot analysis using rabbit polyclonal anti-human IL-7 (Santa Cruz, CA, USA). As shown in Figure 1a , IL-7 bands of expected size (25 kDa) were detected in lysates of MSC-IL-7 cells, whereas no protein was detected in the supernatant of MSC-AdEGFP cells or negative control MSCs.
Detection of hIL-7 mRNA and protein expression in recipient mice
Levels of IL-7 in the serum of mice transplanted with MSC-IL-7 (5 Â 10 6 /mouse) were confirmed by enzymelinked immunosorbent assay (ELISA) at days 1, 3, 7, 10, 20, 30, 50 and 100 post transplant (Figure 1b) . Transplanted mice have high levels of hIL-7 in their serum from day 1 to 20 post transplant, which ranged from 7579 to 125715 pg/ml. Then the IL-7 level declined rapidly to 2075 pg/ml, significantly higher than that in normal mice (8 pg/ml for mouse IL-7), and persisted up to 100 days after transplantation. This result is consistent with the characteristics of MSCs providing stable long-term gene expression.
Reverse transcription-PCR method was performed to detect hIL-7 gene transcription in different organs of recipient mice. Figure 1c shows that hIL-7 cDNA was detected in different tissues driven from bone marrow, spleen and thymus of mice that received 5 Â 10 6 MSC-IL-7, whereas no bands were found in BMT control mice organs.
Effects of MSC-IL-7 on the absolute number of thymocytes, spleen cells and their subsets in allogeneic bone marrow transplantation recipient mice
In the preliminary experiments, recovery of CD4+ T-cell numbers was compared in mice that received different , 5 Â 10 6 , 1 Â 10 7 /mice). Significant dose effects could be detected (data not shown). In this study, we chose a medium dose of 5 Â 10 6 MSC-IL-7 cells per mouse and evaluated their effects on immune reconstitution. To determine the effect of MSC-IL-7 on T-and B-cell development following allo-BMT, lethally irradiated recipient mice C57BL/6 were given 1 Â 10 7 T-cell-depleted bone marrow cells (BMCs) from BALB/c mice with or without 5 Â 10 6 MSC-IL-7 cells. After allo-BMT, the animals were killed at weekly intervals for examination of lymphocyte reconstitution. As shown in Table 1 , a significant increase in total thymocyte numbers was observed in MSC-IL-7 co-transplanted mice compared with MSC group and BMT control by week 4 after allo-BMT (Po0.01 vs Po0.001, respectively), and this difference persisted throughout the duration of the experiment (week 10; data not shown). Previous reports have shown that pre-BMT conditioning treatment could result in a block in thymic differentiation with the increased frequency of double-negative (DN) cells and the decreased frequency of double-positive (DP) cells. 21 Similarly, our results also suggested that thymocyte phenotypes in the BMT or MSC control group differed markedly from those of normal mice. There was a shift towards immature thymocytes. As shown in Table  1 , the mean percentage of DN cells was 45 and 28% in the BMT and MSC control mice, respectively, as compared with 3% in the normal mice (Po0.001). The percentage of DP cells was 23 and 39% in the BMT and MSC recipient mice as compared with 90% in the normal group (Po0.001). However, in MSC-IL-7-treated mice, thymocyte subpopulations returned to almost normal levels. The mean percentages of DN, DP, CD4+SP (single positive) and CD8+SP thymocytes were 6, 78, 11 and 5%, respectively. So these results suggest that MSC-IL-7 facilitates the differentiation of immature thymocytes.
As shown in Table 2 , at week 4 after allo-BMT, both MSC-IL-7-and MSC-treated mice showed a marked increase in the number of total splenocytes, CD8+ cells, CD4+ T cells and B220 cells as compared with BMT-alone recipients. Furthermore, MSC-IL-7 co-transplantation led to 4.5-fold increase in CD4+ T-cell number compared with BMT control, and this difference persisted over week 10 when other differences became insignificant (data not shown), suggesting that MSC-IL-7 may have preferential effects on CD4+ T-cell reconstitution.
MSC-IL-7 potently up-regulates thymopoiesis and peripheral expansion
Recently, episomal DNA circles created by the process of a TCR gene rearrangement during T-cell regeneration have been proposed as a marker for recent thymic emigrants (RTE) in assessing thymic function. 22 These circles, named TCR rearrangement excision circles (TRECs), are stable, are neither degraded nor replicated with cellular division, but are diluted with each cellular division. In this study, we examined thymic TREC total number and splenic TREC frequency to evaluate thymopoiesis and peripheral expansion. As shown in Figure 2 , transfusion of MSC-IL-7 cells into allo-BMT recipient mice resulted in a significant increase in thymic total Po0.05 compared with allo-BMT control mice. Abbreviations: Allo-BMT ¼Allogeneic bone marrow transplantation; MSC ¼ Bone marrow stromal cell. Allo-BMT recipient mice were humanely killed at week 4 after transplantation and total splenocyte counts were calculated and each lineage was analyzed using multicolor flow cytometry using CD4-FITC, CD8+PE and CD45R/B220-Cy-5. Po0.05 compared with allo-BMT control mice.
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TREC number by roughly 4.7-fold compared with BMT control mice, and MSC-treated mice also showed an increased level of thymic TREC but not significant compared with BMT control (Figure 2a) . Similarly, the frequency of TREC in splenocytes was enhanced by almost 3.1-fold in MSC-IL-7-treated recipients, and 1.2-fold in MSC-treated mice compared with BMT control (Figure 2b) . The above data supported our hypothesis that co-transplantation of MSC-IL-7 improves immune reconstitution through enhancing both thymopiesis and peripheral expansion of mature T cells, and indicated that the thymic-dependent pathway contributes much more to T-cell regeneration than peripheral expansion. Further observation showed that at week 10 after allo-BMT, thymus size was noticeably enlarged in MSC-IL-7-treated mice compared with MSC recipients and BMT-alone recipients. Histologic analysis demonstrated an enlarged area of cortex in which immature thymocytes differentiated and proliferated in the thymus taken from MSC-IL-7-treated mice ( Figure 2d ) compared with BMT control groups. Changes in the thymic cytoarchitecture of MSC-treated mice were not detectable when compared with BMT-alone recipients (data not shown). In addition, no significant differences were detected in the size or cytoarchitecture of spleens between the groups (Figure 2e and f), which is consistent with the previously described restoration of splenocytes.
Restoration of immune function in MSC-IL-7-treated mice
In some cases, immune deficiency after transplant continues even after peripheral lymphocytes return to normal levels, suggesting that a T-cell dysfunction occurs in the post-transplant period. In order to assess the effects of MSC-IL-7 on T-cell function restoration, we determined the proliferative responses of reconstituting thymocytes and splenocytes at week 10 after allo-BMT by stimulation with ConA. Figure 3a shows that a higher thymocyte proliferative response to ConA was observed in MSC-IL-7-treated recipients compared with BMT control. In contrast, we could not detect any significant differences in ConA-stimulated proliferation of splenocytes between experimental groups, suggesting that co-transplantation of MSC-IL7 accelerated immune reconstitution after allo-BMT mainly through enhancing thymopoiesis. We further analyzed the changes of antigen-specific response after allo-BMT. The results are shown in Figure 3b and c, and suggest that co-transplantation of MSC-IL-7 cells resulted in a significant enhancement in delayed-type hypersensitivity (DTH) reaction (Po0.01) and antibody production capacity (PFC) (Po0.001) compared with BMT control. In agreement with these results, foodpad histology showed that there were much more inflammatory cells infiltrated in the MSC-IL-7-treated mice than BMT control, as shown in Figure 3d and e. Similar to Effect of MSC-IL-7 treatment on the ability to reject third-party or HY-disparate skin grafts
To further investigate whether reconstituting lymphocytes after allo-BMT have any functional relevance in vivo, we transplanted skin grafts of C3H mice, a foreign antigen to test immune function in vivo, into recipients by week 4 after transplantation. The survival of thirdparty skins was then followed. As shown in Figure 4a , administration of MSC-IL-7 cells significantly shortened the time required to reject the third-party skin grafts in allo-BMT recipients compared with BMT control (median survival time: 15 vs 23 days, Po0.01). In another group, female tail skins of C57BL/6 mice instead of third-party skin grafts were transplanted into male C57BL/6 mice following allo-BMT. As described previously and shown in Figure 4b , normal C57BL/6 mice reject HY-disparate skin grafts within 8 weeks, 23 whereas allo-BMT recipients without MSC-IL-7 treatment are unable to reject these grafts until week 15. And co-transfusion of MSC-IL-7 cells accelerated the rate of HY-disparate skin graft rejection by approximately 4.5 weeks compared with BMT control. These results suggest that immune competence for even stringent antigens such as minor histocompatibility antigen (HY) can be significantly restored by co-transplantation of MSC-IL-7 cells following allo-BMT.
MSC-IL-7 markedly alleviates graft-versus-host disease
Apart from its effects on immature thymocytes and developing T lymphocytes, IL-7 has potent effects on homeostatic expansion of mature T lymphocytes in the periphery. This raises the possibility that IL-7 administered into allo-BMT recipients could have a stimulatory effect on mature T cells of donor origin to aggravate GVHD. And indeed some studies have demonstrated that systemic administration of IL-7 could worsen the development of GVHD in the setting of allo-BMT. 23 To analyze this potentially detrimental effect of co-transfusion of MSC-IL-7, we induced moderate GVHD in our recipients by adding 5 Â 10 5 splenic donor T cells to the allogeneic TCD bone marrow grafts. As shown in Figure 5a , MSC-IL-7-and MSC-treated mice only showed transient slight weight loss between weeks 1 and 2 due to irradiation toxicity, and then their weight began to increase. In contrast, a significant weight loss was observed in mice that only received T-cell-depleted BMCs plus donor splenic T cells. Analysis of mortality associated with GVHD suggested that control mice receiving splenic T cells but not MSC-IL-7 have approximately 40% lethality from GVHD. However, MSC-IL-7 co-transplantation could protect the recipient mice from GVHD-induced mortality, with 90% recipients displaying long-term survival (Figure 5b ). This observation demonstrated that co-transplanting MSC-IL-7 or MSC could prevent or alleviate GVHD occurrence, which is consistent with previous reports suggesting that MSCs could suppress immune response significantly. 18 In order to further confirm the protective effects of MSC-IL-7 on GVHD, we undertook an extensive histologic analysis of animals receiving donor splenic T cells with or without MSC-IL-7 cells on day 14 after allo-BMT, because induced GVHD occurs primarily during the first 14 days after allo-BMT. 25 Histologic analysis revealed that there was no evident lymphocyte infiltration in all GVHD target tissues of MSC-IL-7-and MSC-treated mice even 
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A Li et al after adding 5 Â 10 5 donor splenic T cells. However, as expected, allo-BMT recipients receiving splenic T cells showed severe inflammation in GVHD target organs. Figure 5 shows a liver section from representative mice. Taken together, a conclusion can be drawn from these results that co-transplantation of MSC-IL-7 can prevent or alleviate GVHD in the setting of allo-BMT.
Discussion
The most efficient way to reconstitute T-cell immunity after allo-BMT is dependent on T-cell regeneration from donor-derived hematopoietic stem cells via thymopoiesis, which involves rearrangement of T cell receptor genes, positive and negative selection in thymus. T cells regenerated by this way maintain repertoire diversity and immunocompetence to a variety of antigens. 26, 27 Therefore, there is currently substantial interest in developing new therapeutic agents to accelerate immune reconstitution by enhancing thymopoiesis weakened or damaged by age and pretransplant conditioning treatment. Until recently, IL-7 has been identified as a potent and unique thymopoietic cytokine and has been shown in various genetic models to be essential for the survival, proliferation and differentiation of immature thymocytes. However, the effect of systemic IL-7 administration on thymic function after allo-BMT is still a controversial issue. Several groups have observed a beneficial effect of IL-7 on thymopoiesis after transplantation, 11,13 whereas others did not, 28 depending on the dose and length of IL-7 administration. To address this issue and develop a more beneficial and natural approach of IL-7 treatment, we used MSCs as vehicles to deliver IL-7 protein into hematopoietic location for a long period. It can be seen from Figure 1b that co-tranpslantation of 5 Â 10 6 MSC-IL-7 cells per mice could maintain this cytokine in mice serum at an effective concentration for a long period, which is higher than normal level and much lower than systemic administration of high dose of IL-7. It has been demonstrated that co-transplantation of donor MSCs contributes largely to successful allo-BMT by reconstructing hematopoietic microenvironment via homing to bone marrow of recipients. 29 Similarly, donor MSCs can also migrate into thymus and other peripheral lymphoid tissues. 30 In this study, we suppose that MSC-IL-7 cells could deliver an effective concentration of IL-7 into intrathymus to restore thymopoiesis of allo-BMT recipients by reconstructing thymic microenvironment. Indeed, hIL-7 mRNA was detected within the thymus of recipient mice and a significant enhancement in thymopoiesis was observed in our animal model, which gave an affirmative support to our hypothesis.
Administration of IL-7 could result in a significant increase in the number of peripheral T lymphocytes, as demonstrated by a number of previous reports. [11] [12] [13] Our data also confirmed these effects of IL-7 by showing an improved restoration in total spleen cells and lymphocyte subsets in MSC-IL-7-transplanted mice. Most importantly, MSC-IL-7 treatment appears to have a preferential effect on CD4+ T-cell restoration as opposed to CD8+ T cells, as shown in Table 2 . This may have important implication in clinic. Because, in the setting of allo-BMT, reconstitution of CD4+ T cells was severely impaired and its number was inversely related to the risk of developing infections. 31, 32 In addition, this reconstitution of CD4+ T cells was accompanied by functional recovery in our recipients (Figure 3) .
Apart from its effects on peripheral expansion of mature lymphocytes, IL-7 plays a crucial role in thymopoiesis by modulating the differentiation of immature thymocytes. Our data also demonstrated that MSC-IL-7 treatment resulted in a dramatic increase in thymocyte numbers and proliferative responses to mitogen, and normalization of thymocyte subpopulations (Table 1) . Furthermore, enhanced thymic function was supported by increased intrathymic total TREC numbers, and enlarged size and modified cytoarchitecture of thymus in recipient mice receiving MSC-IL-7 treatment compared with BMT control (Figure 2 ). Taken together, it was suggested that restoration of immune competence in recipient mice receiving MSC-IL-7 treatment was accomplished through both thymic-independent and thymicdependent pathways. In contrast to our results, some investigators have failed to observe the thymopoietic effects of systemic administration of exogenous IL-7 following allo-BMT. 28 We suppose that this difference may be explained by the following reasons. In their experiments, high dose of exogenous IL-7 was used for a short period in order to avoid adverse effects associated with high concentrations of IL-7. As previously Figure 4 Faster rejection of skin grafts in allo-BMT recipient mice receiving MSC-IL-7 cells. (a) At week 4 after allo-BMT, recipient mice were grafted with third-party skin from C3H mice as a model to test immune response to foreign antigens. MSC-IL-7-treated mice completely rejected allogeneic skin grafts by day 15 after graft, faster than that seen in allo-BMT control, whereas no significant differences were observed between the MSC group and allo-BMT control. At the same time, HY-disparate skin from female C57BL/6 mice was transplantated into allo-BMT male recipient mice (b). Cotransplantation of MSC-IL-7 resulted in significant faster rejection of female skin grafts compared with allo-BMT control group. Moreover, MSCs treatment also shortened the time required to reject such skin grafts as compared with the allo-BMT control mice (complete rejection in week 14 vs week 15, respectively).
IL-7 gene therapy enhances immune reconstitution A Li et al
described, in the setting of T-cell depletetion, a high concentration of IL-7 systemically administrated can be rapidly exhausted by homeostatic proliferating T cells in the periphery. Additionally, it is not clear if high circulating levels of IL-7 can infiltrate into the thymus to exert its local effects. In a previous report, it has been demonstrated that pre-BMT radiation could result in a markedly decreased intrathymic IL-7 production because of the loss of IL-7-producing thymic stromal cells. 21 Although there was an increase in the circulating level of IL-7 in the BMT recipients, there was a block in their thymocytes differentiation also. In our experiments, donor-derived bone MSCs were used as vehicles of gene therapy. In addition to their easy isolation and expansion in vitro, MSCs have been found to be transplantable by some groups. For example, Pereira et al. 33 have demonstrated that donor-derived MSCs could distribute to various organs of recipients, including spleen, thymus, liver, bone marrow and even lung, in different animal models when certain number of ex vivo-expanded MSCs were transplanted into the recipients. Our observation also confirmed that MSCs could mediate hIL-7 expression in immunological and hematopoietic organs of recipient mice. Therefore, it is most likely that the enhanced intrathymic IL-7 concentration plays a potent effects on thymopoiesis.
In the present study, MSCs are not merely used as a gene delivery system, but possess many intrinsic biologic activities, which are attractive for investigators engrossed in clinical transplantation. In addition to their homing capacity, another important characteristic of MSCs is that they are poor antigen-presenting cells and do not express major histocompatibility complex class II or co-stimulatory molecules. 34 A number of in vitro studies have demonstrated that MSCs can dramatically suppress mitogen-induced T-cell proliferation, 35 and these immunosuppressive effects have been confirmed by in vivo experiments. 36 For example, previous reports have suggested that in the setting of allo-BMT, co-tranplantation of donor-derived MSCs may prevent or ameliorate GVHD by directly exerting their immunosuppressive effect. In some studies, even third-party MSCs have been transplantated, and showed similar protective effects from GVHD. 37 In agreement with these reports, our results indicate that MSC-IL-7 treatment results in a significant decrease in GVHD mortality and absence of clinical signs of GVHD ( Figure 5 ) with the given dose of donor splenic T cells. However, these results are conflicting with other reports, which demonstrated that systemic administration of IL-7 after allo-BMT worsened GVHD. 24 A potential explanation for this difference may be that in their experiments, pharmacologic doses of IL-7 were used for long periods which results in much more higher level of IL-7 above the normal. According to a recent study by Alpdogan et al., 38 peripheral donor mature T cells can be divided into two populations, one is alloreactive T cells with decreased expression of IL-7 receptor, and the other is nonallo- 
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A Li et al reactive T cells with high-affinity IL-7 receptor expression. Therefore, moderate levels of IL-7 stimulate nonalloractive T-cell proliferation with free of GVHD, as observed in our experiments, and when a high dose of IL-7 was administrated into allo-BMT recipient, GVHD will be induced or worsened by stimulating alloreactive donor mature T cells. A potential possibility of GVHD must be further investigated carefully when higher doses of donor T cells or T-cell-repleted BMCs were used in the setting of allo-BMT.
In conclusion, MSC-mediated IL-7 gene therapy further provides direct evidence supporting IL-7 as a promising immunorestorative agent in the setting of allo-BMT. Compared with systemic administration of IL-7, our reported strategy may be more beneficial and feasible in clinical transplantation, because this strategy has potent effects on both enhancing homeostatic expansion of peripheral T cells and thymic-dependent T-cell regeneration, while preventing GVHD occurrence. Mice were used at 8-12 weeks of age in BMT experiments. The mice were kept in a specific pathogen-free facility and were supplied with autoclaved food and acidified water throughout the study. Female guinea-pigs (250 g) were used for the preparation of complement.
Materials and methods

Mice
All care and handling of animals complied with the guidelines set forth by the Animal Care Ethics Committee of Peking University Heath Science Center.
Bone marrow stromal cells
Isolation and culture of mouse MSCs were performed using a modification of a protocol described previously. 39 Briefly, BMCs, harvested from 8-to 12-week-old-BALB/c mice, were cultured in Collagen type 1 Cellware flasks containing a-minimal essential medium supplemented with 10% horse serum, 10 À6 M hydrocortisone and antibiotics. After 3 days, nonadherent cells were removed by two to three washes with PBS and adherent cells further cultured in complete medium supplemented with 10 ng/ml EGF, 10 ng/ml PDGF-BB and 1000 U/ml of leukemia inhibitory factor for 2 weeks. Then, the adherent cells were collected from the surface of the flasks by trypsin-EDTA treatment. The cell suspensions were prepared and used for gene transduction.
Construction of adenovirus vector and transduction of murine bone marrow stromal cells
A 533 bp IL-7 gene was amplified by polymerase chain reaction (PCR) method from a plasmid pSVK3-IL-7 containing human IL-7 cDNA (kindly provided by Dr Qinghan Li, Institute of Medical Biology, CAMS/PUMC, Kunming, China) using the following primers: sense, 5 0 -GCG GGA TCC TAT GTT CCA TGT TTC-3 0 ; antisense, 5 0 -GCG GTC GAC TCA GTG TTC TTT AGT G-3 0 , for 30 cycles of 941C at 45 s, 551C at 45 s and 721C at 45 s. The PCR product was digested with BglII and XhoI (Promega Madison, WI, USA) and subcloned into the same treated plasmid pTrack-CMV to generate pTrack-CMV-IL-7. The presence of an open reading frame for human IL-7 was verified by sequencing. Then, a recombinant adenovirus vector containing IL-7 cDNA was made by co-transfection of the plasmid pTrack-CMV-IL-7 and the adenoviral genome plasmid pAdEasy-1 into competent BJ5183 Escherichia coli (a gift from Dr Tong-chuan He, The Howard Hughes Medical Institute) by electroporation. The pAdIL-7 vector was subsequently transfected into 293 cells with Lipofectin reagent (Invitrogen, Carlsbad, CA, USA) to generate AdIL-7. Then AdIL-7 was propagated in 293 cells according to standard protocols as described previously. 40 Viral titers were determined by plaque assay on 293 cells and reached up to 10 10 plaqueforming units (PFU) per milliliter. Bone marrow stromal cells were prepared as described above, and were transduced in suspension with AdVIL-7 or AdV at 1000 multiplicity of infection at 371C in 5% CO 2 for 2 h. More than 90% of transduced MSCs analyzed by FACS were GFP positive.
Allogeneic bone marrow transplantation
For BMT experiments, BMCs from BALB/c mice were flushed from tibias and femurs with iced complete RPMI1640 medium. Bone marrow cells were depleted of T cells by incubation with anti-thy-1.2 for 30 min at 41C followed by incubation with guinea-pig complement for 1 h at 371C and washed twice before use. Bone marrow depleted of T cells was confirmed by flow cytometry to contain less than 2% residual T cells. Recipient C57BL/6 mice received 950 cGy total body irradiation from a 137 Cs irradiation source. This dose of irradiation proved to be fatal to 100% of mice by day 12 when no marrow support was given. Then, allogeneic T-cell-depleted marrow cells (1 Â 10 7 cells/mouse) from donors were injected into the tail vein of recipient mice within 12 h. For some experiments, 5 Â 10 5 purified splenic T cells from donor mice were injected along with BMCs to induce moderate GVHD. Recipients were monitored daily for survival and clinical signs of GVHD. Body weight was recorded every 7 days. Biopsies were taken from skin, gut, and liver on day 14 after induction of GVHD.
Interleukin-7 production
The production of human IL-7 from transduced MSCs in the serum of transplanted mice and in the supernatant of cultured MSC-IL-7 cells was determined using ELISA kits obtained from R&D Systems, and assays were performed according to the manufacturer's protocol.
Flow cytometric analysis
Thymic or splenic single-cell suspensions (0.5-1 Â 10 6 cells) were incubated with murine monoclonal antibodies specific for CD4, CD8, CD3+ and B220 antigens. Antibodies were used at 1:100 dilution, and cells were washed with PBS supplemented with 2% fetal bovine serum (HyClone, Logan, UT, USA) and then fixed in 0.4% paraformaldehyde. Immunophenotypic analysis of stained and fixed cells was performed on a fluorescenceactivated cell sorter (FACScan; Becton-Dickinson, San Jose, CA, USA) using CELLQUEST software. Results are presented as percentage or an absolute count for each lymphocyte subset. The antibodies used in this study were FITC-conjugated anti-CD4, PE-conjugated IL-7 gene therapy enhances immune reconstitution A Li et al anti-CD8, B220-Cy-5 and Isotype control antibody Mouse IgG1-PE (Sino-American Biotechnology Co, Beijing, China).
Delayed-type hypersensitivity assay
Delayed-type hypersensitivity assays were performed 4 days after sensitization with SRBC. Allo-TCD-BMT recipient mice C57BL/6 were sensitized with 10 8 SRBC given intravenously. Four days after sensitization, mice were challenged by injection directly into the right hind footpad with 10 8 SRBC in 25 ml PBS. Twenty-four hours after challenge, the DTH response was quantified by measuring and comparing changes in the thickness of the challenged footpad and the contralateral footpad, which had received 25 ml PBS alone. Comparable measurements were performed in a parallel group of mice that had been challenged but not sensitized. Some samples were used for histologic analysis.
Plaque-forming cell assay
Four days after immunization with SRBC, the plaqueforming cell (PFC) assay was performed using spleen cells from immunized mice, as described previously. 41 Aliquots of spleen cells, in RPMI-1640 medium, were added to glass test tubes held at 471C in a constant temperature water bath. The tubes contained agar and 0.05% diethyl aminoethyl dextran in Earle's balanced salt solution, SRBCs and gunea-pig complement. The content of each test tube was mixed by vortexing, poured into a 100 mm Costar Petri dish and covered with a 45 Â 50 mm glass coverslip. The Petri dishes were incubated for 3 h at 371C and 5% CO 2 in an incubator, then the number of plaques were counted. The data are presented as the number of PFC/spleen.
T-cell receptor excision circle analysis
Quantification of T-cell receptor excision circles (TRECs) in thymus was performed by real-time PCR as described previouly. 42 In short, genomic DNA from whole thymus tissue was prepared by homogenization in 1 ml TRIZOL reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Polymerase chain reaction contained 0.5 mM of each primer, 0.3 mM of fluorescent probe, 1 Â Platinum Quantitative PCR Supermix-UDG (Invitrogen) and Blue-636 reference dye. Amplification was performed in triplicate on an ABI Prism 7700 Sequence Detection system (Perkin-Elmer) and analyzed using associated software. Polymerase chain reaction conditions were 501C for 2 min, 951C for 5 min, then 40 cycles of 951C for 15 s and 601C for 1 min. Sequences of primers and probe used were as follows: sense primer, 5 0 -CCAAGCTGACGGCAGGTTT-3 0 ; antisense primer, 5 0 -AGCATGGCAAGCAGCACC-3 0 ; probe, FAM-5 0 -TGC TGTGTGCCCTGCCCTGCC-TAMRA-3 0 . Primers were synthesized by Invitrogen and fluorescent probe by Biosource (Camarillo, CA, USA). The total number of TREC was calculated by multiplying the TREC frequency by the number of cells in the population. 
Proliferation assays
Skin grafting
Skin grafting was performed as described previously. 43 Briefly, BMT recipients were grafted with 0.5-cm patch of tail skin over the thorax and covered with a pressure dressing for 7 days. Then, bandages were removed and a blind observer monitored graft rejection. Complete rejection was defined as more than 80% of the graft surface area involved.
Histologic analysis
At certain time points, the recipient mice were humanely killed and their tissues were removed and fixed in 10% formalin solution and embedded in paraffin. Thick sections (5 mm) were cut and stained with hematoxylin and eosin (H&E). Pathologic assessment of degree of inflammation was made by a pathologist unaware of the origin of the sections.
Statistical analysis
All values are expressed as mean7s.d. The Mantel-Cox log-rank test was used for survival data and all other statistical analysis was performed with unpaired Student's t-test. A P-value of less than 0.05 was considered to be statistically significant.
